678 Updated safety and efficacy of toripalimab combined with cetuximab in platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC): a phase Ib/II clinical trial

西妥昔单抗 医学 内科学 耐火材料(行星科学) 头颈部鳞状细胞癌 肿瘤科 临床终点 队列 无进展生存期 临床研究阶段 临床试验 头颈部癌 胃肠病学 放射治疗 化疗 癌症 物理 结直肠癌 天体生物学
作者
Ye Guo,Qiang Li,Desheng Hu,Song Qu,Youhua Zhu,Meiyu Fang,Wantao Chen,Chuan-Zheng Sun,Hao Jiang,Jingfeng Zong,Jinguan Lin,Siyang Wang,Wei Wang,Chuan Jin,Guochun Cao,Minghua Ge,Xiaoming Huang,Xudong Wang,Zhiming Li,Mo Wang,Xianming Luo,Shuang-Hui Wei,Yuteng Shen
标识
DOI:10.1136/jitc-2023-sitc2023.0678
摘要

Background

PD-1 inhibitors and EGFR inhibitors are effective and may provide potential synergy in R/M HNSCC. An open-label, multicenter phase Ib/II study of toripalimab (a humanized IgG4K monoclonal antibody specific for PD-1) with cetuximab was conducted in platinum-refractory or PD-L1 positive previously untreated R/M-HNSCC (NCT04856631). Here we report the results of Cohort A (platinum-refractory).

Methods

Eligible patients with R/M HNSCC progressed upon 1st-line platinum-containing treatment or developed R/M disease within 6 months of platinum-containing neo-adjuvant/adjuvant or chemo-radiation therapy who had no prior immunotherapy or EGFR inhibitors therapy were enrolled. Toripalimab was administered at 240mg intravenously (IV) Q3W and cetuximab was given as a loading dose of 400mg/m2 IV followed by 250mg/m2 QW. The primary endpoint was objective response rate (ORR) by an independent review committee (IRC) per RECIST v1.1. Secondary endpoints included ORR, disease control rates (DCR), duration of response (DOR), progression-free survival (PFS) by the investigators and IRC, overall survival (OS), and safety.

Results

By the data cutoff date of Apr. 14, 2023, a total of 45 patients including 35 (77.8%) males were enrolled in Cohort A, with the median follow-up duration of 10.0 months. The median age of the patients was 59 (range 32–74) years. Eighteen (40.0%) patients had distant metastases and 31 (68.9%) were PD-L1 CPS ≥1. As assessed by the IRC, the confirmed ORR was 60% (95% CI 44.3%, 74.3%) with 1 CR and 26 PR, and the median DOR was 17.9 (95% CI 7.8, NA) months, the median PFS was 9.9 (95% CI 4.2, NA) months, 12 months PFS rate was 40.7%. Similar results were seen per investigators' assessment. The median OS was 15.4 (95% CI 8.5, 17.7) months, 12 months OS rate was 54.4%. Patients with positive PD-L1 expression (CPS≥1) may benefit more than negative patients (ORR: 64.5% vs 40%, median PFS: 10.4 m vs 4.0 m, median OS: 15.4 m vs 11.7 m). Forty-two (93.3%) patients experienced treatment-related adverse events (TRAEs). Eleven (24.4%) patients experienced immune-related adverse events (irAEs). Ten (22.2%) patients occurred Grade≥3 TRAEs and no Grade≥3 irAEs occurred. No fatal AEs related to the study treatment was reported.

Conclusions

Toripalimab combined with cetuximab were well tolerated and showed promising clinical efficacy in patients with R/M HNSCC.

Trial Registration

NCT04856631

Ethics Approval

The study obtained ethics approval from Shanghai East Hospital Drug clinical Trial Ethics Committee [[2020]&x4E34;&x5BA1;&x7B2C; (072) &x53F7;], and participants gave informed consent before taking part.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
细心的盼易完成签到 ,获得积分10
刚刚
英俊的含蕾完成签到 ,获得积分10
1秒前
龙行天下完成签到,获得积分10
3秒前
小蘑菇应助WN采纳,获得10
4秒前
5秒前
5秒前
东郭一斩完成签到,获得积分10
5秒前
量子星尘发布了新的文献求助10
5秒前
平安喜乐发布了新的文献求助10
6秒前
左孤容完成签到 ,获得积分10
6秒前
wanmiao12完成签到,获得积分10
8秒前
yu发布了新的文献求助10
9秒前
mmmmm完成签到,获得积分10
10秒前
洁净白容完成签到,获得积分10
10秒前
大个应助孟孟采纳,获得10
10秒前
小镇的废物完成签到,获得积分10
10秒前
柴郡喵完成签到,获得积分10
11秒前
SYLH应助小熊采纳,获得10
12秒前
妹妹发布了新的文献求助10
12秒前
12秒前
赘婿应助我必定发nature采纳,获得20
13秒前
Ava应助kofbird采纳,获得50
14秒前
zz完成签到,获得积分10
14秒前
星辰大海应助ybwei2008_163采纳,获得10
14秒前
16秒前
16秒前
QJYKKK完成签到,获得积分10
16秒前
composite66完成签到,获得积分10
16秒前
ccchao发布了新的文献求助30
17秒前
充电宝应助十三采纳,获得10
17秒前
大个应助橙橙橙采纳,获得10
17秒前
Dandanhuang完成签到,获得积分10
17秒前
FashionBoy应助孟孟采纳,获得30
19秒前
畅快的刚完成签到,获得积分10
21秒前
21秒前
xxxx完成签到,获得积分10
21秒前
vain发布了新的文献求助10
21秒前
李健应助芒果小鹌鹑采纳,获得10
21秒前
cc完成签到,获得积分10
22秒前
这个名字是不是独一无二完成签到,获得积分10
22秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038569
求助须知:如何正确求助?哪些是违规求助? 3576279
关于积分的说明 11374944
捐赠科研通 3305979
什么是DOI,文献DOI怎么找? 1819354
邀请新用户注册赠送积分活动 892698
科研通“疑难数据库(出版商)”最低求助积分说明 815048